Regeneron plans to start COVID-19 antibody trial in early summer

17 March 2020
regeneron-location-big

US biotech company Regeneron (Nasdaq: REGN) has provided an update on its coronavirus (COVID-19) antibody program.

The firm is seeking to discover and develop a multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus, which causes the COVID-19 disease, or as treatment for those already infected.

Regeneron scientists have now isolated hundreds of virus-neutralizing, fully human antibodies from the company's VelocImmune mice, which have been genetically-modified to have a human immune system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology